Patients
Physicians
Sponsors
Oncologists
About Us
News
ENG
Last updated 3 months ago
Share
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
240 patients around the world
Available in
Spain, United States, Argentina
argenx
240
Patients around the world
This study is for people with
Inflammatory Myopathies
Dermatomyositis
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Inclusion criteria
Exclusion criteria
See details
Contact us
Contact us
Study
ALKIVIA
Sponsor
argenx
Conditions
Dermatomyositis
Requirements
From 18 Years
All Gender
Unique study ID
clinicaltrials.gov
NCT05523167
About us
Our mission
Our team
Partners
FAQs
Medical news
Latest news
Studies
Interviews
Testimonials
Products
UEPM Onco
UEPM Physicians
Links
Downloads
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent